Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for ...
RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications.
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results